Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...

Draft guidance issued for consultation recommends the use of 4 AI technologies to help professionals detect fractures in ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this ...

The updated guideline recommends offering a comprehensive falls assessment and management for people who have fallen in the ...

This topic was considered by the diagnostics advisory committee, which is a standing advisory committee of NICE. Committee members are asked to declare any interests in the test to be evaluated. If it ...

The diagnostics advisory committee considered evidence on digital technologies for assessing attention deficit hyperactivity disorder (ADHD) from several sources, including an external assessment ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

NICE intends to develop tools, in association with relevant stakeholders, to help organisations put this guidance into practice. In addition, NICE will support this guidance through a range of ...

Use QbTest as an option to help diagnose attention deficit hyperactivity disorder (ADHD) in people aged 6 to 17 years. It should only be used with standard clinical assessment by a healthcare ...